GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Torii Pharmaceutical Co Ltd (OTCPK:TRXPF) » Definitions » Short Percentage of Float

Torii Pharmaceutical Co (Torii Pharmaceutical Co) Short Percentage of Float


View and export this data going back to 2009. Start your Free Trial

What is Torii Pharmaceutical Co Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Torii Pharmaceutical Co's Short Percentage of Float

For the Drug Manufacturers - Specialty & Generic subindustry, Torii Pharmaceutical Co's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Torii Pharmaceutical Co's Short Percentage of Float Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Torii Pharmaceutical Co's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Torii Pharmaceutical Co's Short Percentage of Float falls into.



Torii Pharmaceutical Co (Torii Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Torii Nihonbashi Buildingg, 4-1, Nihonbashi-Honcho, 3-chome, Chuo-ku, Tokyo, JPN, 103-8439
Torii Pharmaceutical Co Ltd is a major drug manufacturing company. The company utilizes strategic partnerships with other pharmaceutical companies in order to combine research and marketing functions. Torii's key therapeutic areas include renal diseases, hemodialysis, HIV, skin diseases, and allergens. The vast majority of the company's net mainstay product sales are derived from the renal diseases and hemodialysis operations, followed by HIV. Torii's places its strategic focus on prompt market penetration and expansion of new products as well as maximizing values of mainstay products in each priority area.

Torii Pharmaceutical Co (Torii Pharmaceutical Co) Headlines

No Headlines